Biopharma | January 01, 2026
Savara resubmits FDA application for potential treatment in rare lung disease patients
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
Pandemic was the opportunity for Ayush to develop their science and Ayush did it by developing Ayush 64, etc
Sonowal exhorted young researchers and scientist to work on evidence based scientific research
The foundation has been working closely with the Kidwai Memorial Institute of Oncology on several projects since 2001
Subscribe To Our Newsletter & Stay Updated
